伊米普拉在狗中:在禁食和食条件下口服后的药理学研究
C Fadel1, B Łebkowska-Wieruszewskac2, A Lisowski3
1Department of Veterinary Sciences, University of Pisa, Viale delle Piagge, 2, Pisa 56124, Italy; Department of Veterinary Medicine, Lebanese University, Faculty of Agronomy Bldg., University Street, Dekwaneh, Beirut, Lebanon.
Veterinary journal (London, England : 1997)
|October 3, 2024
概括
这项研究检查了狗的伊米普拉的药理动力学,发现食和禁食状态之间没有显著差异. 药物呈现出快速吸收,但半衰期很短,这表明目前的剂量可能不足以产生持续的治疗效果.
科学领域:
- 兽医药理学 兽医药理学
- 药理动力学 药理动力学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 三环抗抑郁药物伊米普拉用于治疗人类精神疾病,并被考虑用于兽医应用.
- 有限的药理动力学数据存在于狗中的伊米普拉,阻碍了最佳的治疗用途.
- 了解伊米普拉胺在狗中的行为对于其潜在的兽医应用至关重要.
研究的目的:
- 为了确定狗在禁食和食条件下的imipramine的药理动力学.
- 为了研究狗中活性代谢物desipramine的形成.
- 为重新评估犬类的伊米普拉剂量策略提供数据.
主要方法:
- 对六只拉布拉多犬进行口服伊米普拉 (1.5 mg/kg) 的交叉设计 (禁食与食).
- 在48小时内进行连续血液采样,以测量血胺和脱胺度.
- 使用经过验证的高性能液体染色学 (HPLC) 和非分区性药理动力学分析进行量化.
主要成果:
- 伊米普拉胺被快速吸收,最大度 (Cmax) 在0.25小时内达到.
- 在禁食和食状态之间没有观察到显著的药理动力学差异.
- 检测到desipramine但无法量化; imipramine的终端半衰期特别短 (0.25小时).
结论:
- 伊米普拉明在狗中表现出快速吸收和非常短的半衰期.
- 给出的剂量可能只能暂时达到治疗水平.
- 需要进一步的研究,包括静脉注射和多次剂量研究,以优化狗狗的伊米普拉使用.
相关概念视频
Methods for Studying Drug Absorption: In situ
In situ experiments, such as the Doluisio method and Single-Pass Perfusion technique, provide critical insights into drug uptake by simulating in vivo conditions for drug absorption.
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
The Doluisio method involves perfusing a prepared segment of a rat's small intestine with a solution of radiolabeled drug and a non-absorbable marker. This helps to differentiate between absorbed and non-absorbed drug concentrations. The intestinal segment is connected at both ends using tubing and syringes,...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...


